Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells, Relapsed Lymphoma, ANGEL
Epstein-Barr Virus-Related Hodgkin Lymphoma, Epstein-Barr Virus-Related Non-Hodgkin Lymphoma, EBV Positive Plasma Cell Neoplasm
About this trial
This is an interventional treatment trial for Epstein-Barr Virus-Related Hodgkin Lymphoma focused on measuring EBV Positive Hodgkin's Lymphoma, EBV Positive Non-Hodgkin's Lymphoma, EBV Specific Cytotoxic T-Lymphocytes
Eligibility Criteria
INCLUSION CRITERIA: Any patient with EBV positive Hodgkin disease or non-Hodgkin Lymphoma, or plasma cell neoplasms in second relapse regardless of age or sex, in first relapse or with primary disease or in first remission if immunosuppressive chemotherapy contraindicated, e.g. patients who develop Hodgkin disease after solid organ transplantation or if the Lymphoma is a second malignancy e.g. a Richters transformation of CLL. Life expectancy of greater than 6 weeks. No severe intercurrent infection Patient, parent/guardian able to give informed consent Bilirubin <2x normal, SGOT <3x normal, Hgb greater than 8.0 g/L Creatinine <2x normal for age Must have been off other investigational therapy for one month prior to entry in this study. Karnofsky score of greater than or equal to 50. EXCLUSION CRITERIA: Patient with an EBV positive NHL secondary to an acquired immunodeficiency. Patients who are HIV positive Patient, parent/guardian unable to give informed consent Patients with a Karnofsky score of < 50. Patients with a life expectancy of <6 weeks Patients with a bilirubin greater than 2x normal. SGOT greater than 3x normal Patients with a creatinine greater than 2x normal for age Due to unknown effects of this therapy on a fetus, pregnant women are excluded from this research. The male partner should use a condom. Note: Patients who would be excluded from the protocol strictly for laboratory abnormalities can be included at the investigator's discretion after approval by the CCGT Protocol Review Committee and the FDA reviewer.
Sites / Locations
- Houston Methodist Hospital
- Texas Children's Hospital
Arms of the Study
Arm 1
Experimental
Injection of EBV Specific CTLs
Subjects will receive autologous EBV Specific CTLs. Patients that agree will recieve CTLs that have been marked with the neomycin resistance gene.